Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.53
Peer-review started: December 12, 2020
First decision: January 27, 2021
Revised: January 28, 2021
Accepted: March 8, 2021
Article in press: March 8, 2021
Published online: March 25, 2021
Core Tip: Coronavirus disease 2019 represents a terrible, still unsolved, global problem affecting not only the healthcare system but also the economic and social one. All countries are facing and fighting against this pandemic but there is still no specific treatment for its eradication. Recently some nucleotide inhibitors, already approved and employed for the treatment of hepatitis c virus infection, have been repurposed for treatment of severe acute respiratory syndrome coronavirus 2 infection, because of some common features among coronaviruses and hepatitis c virus. Herein briefly I focused on the effects of this compound on coronavirus disease 2019, based on its pharmacokinetic properties and on results of several completed clinical trials.